Wall Street Zen Upgrades Structure Therapeutics to Hold Rating
Investment firm Wall Street Zen has upgraded its rating for Structure Therapeutics (NASDAQ: GPCR) from “sell” to “hold,” as reported on Saturday. This change reflects a shift in sentiment towards the biopharmaceutical company, which focuses on developing innovative oral therapeutics for chronic diseases.
Several other analysts have also recently provided insights into Structure Therapeutics’ performance. On November 28, HC Wainwright reiterated a “buy” rating and set a target price of $60.00. In a separate report on the same day, Morgan Stanley raised its price target from $120.00 to $125.00, maintaining an “overweight” rating. Stifel Nicolaus also increased its price objective from $50.00 to $90.00 and assigned a “buy” rating on December 8.
Conversely, Zacks Research lowered its rating for Structure Therapeutics from “hold” to “strong sell” on October 17. Meanwhile, Lifesci Capital upgraded the stock to a “strong buy” on September 8. Overall, one analyst has issued a “strong buy” rating, eleven have rated it as a “buy,” and two have given it a “sell,” leading to an average rating of “moderate buy” with a target price of $95.78, according to data from MarketBeat.
Recent Financial Performance
Structure Therapeutics announced its quarterly earnings results on November 6. The company reported earnings per share of ($0.37), falling short of the consensus estimate of ($0.36) by ($0.01). Analysts predict that the company will post an earnings per share of (0.82) for the current fiscal year.
Institutional Investment Activity
A number of institutional investors have recently altered their positions in Structure Therapeutics. The State of Wyoming acquired a new stake worth approximately $28,000 in the second quarter. EverSource Wealth Advisors LLC significantly increased its holdings by 530.0% in the third quarter, now owning 1,071 shares valued at $30,000 after buying an additional 901 shares.
National Bank of Canada FI raised its position by an impressive 1,448.2% in the first quarter, bringing its total to 2,957 shares valued at $51,000. Additionally, Assetmark Inc. boosted its stake by 39.9% during the second quarter, now owning 2,877 shares worth $60,000.
PNC Financial Services Group Inc. also increased its position by 29.1%, owning 4,415 shares valued at $92,000 after acquiring an additional 994 shares in the same period. Currently, approximately 91.78% of Structure Therapeutics’ stock is held by hedge funds and institutional investors.
Founded as a clinical-stage global biopharmaceutical company, Structure Therapeutics aims to develop innovative oral therapeutics to address chronic diseases with unmet medical needs. Its lead product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like peptide-1 receptor, which is a validated drug target for conditions such as type 2 diabetes and obesity.
This combination of analyst upgrades and institutional interest reflects a dynamic landscape for Structure Therapeutics, indicating potential for growth and development in the biopharmaceutical sector.
